Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. - Wikidata - awgldk - TriplyDB

Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.

Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.

http://www.wikidata.org/entity/Q34433867

about

Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis Bone Marrow T Cells and the Integrated Functions of Recirculating and Tissue-Resident Memory T Cells Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases Epidemiology and burden of alopecia areata: a systematic review Novel insights into the role of immune cells in skin and inducible skin-associated lymphoid tissue (iSALT)Essential biphasic role for JAK3 catalytic activity in IL-2 receptor signaling Current and future treatments of alopecia areata and trichotillomania in children.CD49a Expression Defines Tissue-Resident CD8+ T Cells Poised for Cytotoxic Function in Human Skin.SOCS3 treatment prevents the development of alopecia areata by inhibiting CD8+ T cell-mediated autoimmune destruction The Changing Landscape of Alopecia Areata: The Translational Landscape.The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm.Emerging treatments in alopecia.Pharmacologic inhibition of JAK-STAT signaling promotes hair growth Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers.Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata.Crisp1 and alopecia areata in C3H/HeJ mice Drug discovery for alopecia: gone today, hair tomorrow Hair regrowth in alopecia areata patients following Stem Cell Educator therapy.Treatments options for alopecia.Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib The impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasms dsRNA Released by Tissue Damage Activates TLR3 to Drive Skin Regeneration.JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases Treating Alopecia Areata: Current Practices Versus New Directions.Multilayered T-cell memory in human skin.Master regulators of infiltrate recruitment in autoimmune disease identified through network-based molecular deconvolution.Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA).Dietary vitamin A regulates wingless-related MMTV integration site signaling to alter the hair cycle.Transient Efficacy of Tofacitinib in Alopecia Areata Universalis Functional Interpretation of Genome-Wide Association Study Evidence in Alopecia Areata.The Diagnosis and Treatment of Hair and Scalp Diseases.Molecular signatures define alopecia areata subtypes and transcriptional biomarkers IL-15 functions as a danger signal to regulate tissue-resident T cells and tissue destruction 3-Deoxysappanchalcone Promotes Proliferation of Human Hair Follicle Dermal Papilla Cells and Hair Growth in C57BL/6 Mice by Modulating WNT/β-Catenin and STAT Signaling.Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction.Remarkable Improvement of Nail Changes in Alopecia Areata Universalis with 10 Months of Treatment with Tofacitinib: A Case Report.Skin Diseases in Laboratory Mice: Approaches to Drug Target Identification and Efficacy Screening.Alopecia areata: Animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strategies.Tofacitinib for the treatment of moderate-to-severe psoriasis.

P2860

Q26765028-901FB73C-B858-4C95-B366-2F9677E71871 Q26766714-2BE3715F-E6E4-44EA-A5E3-5ECCEB972B09 Q26775111-ED0DB517-263E-4661-AB5D-99B8DE55B936 Q26798616-86F42AEB-43E7-49F7-80DC-C375648C4BFE Q28081241-6980965B-D042-44DC-AD64-059286CB36C1 Q28834529-F10BBD0C-2DD9-4B8D-985C-9F5DBA8BEB13 Q30248651-5E3A8186-D3B8-4695-A3E0-F8D83386D80F Q33390838-2E0F4964-9107-4B52-8DC9-854F5CBAA59B Q33779510-6EA0572D-ED28-49DB-BEE1-8BC7FDAA264F Q33890781-E75277CA-9800-4C6F-B3C4-51FEB7F7CA78 Q33890805-2ABF3F78-A4D1-4488-BC6B-EE8C36766400 Q34444226-45BE822A-78D7-4329-9403-6CF0B1025839 Q34502857-9CE4A02E-3D04-4C28-98CD-DA8EE1C447C0 Q34523843-6E7CBA17-61DC-48AF-BBDD-C77FA61835BF Q34541893-7AD2C004-6686-41A4-AD63-1E8F20A48021 Q34541899-1E5380F7-2597-4824-98B9-9895AB303750 Q34674700-DA107AED-0A56-4E25-9510-2D03110F4F67 Q35118394-2F1A957E-EA31-4DD0-A997-295462CD24C5 Q35562516-9EF9429F-F297-4C6C-85E2-FB6635C5E9DA Q35762063-C830774F-83AB-4AB1-83D1-3913505A894D Q35800753-C3B3D9DF-41EB-46FB-865A-7680F3CDCAD2 Q35841839-8BD4A8E9-7221-4D43-973D-BB248A4C2943 Q35931137-BEF85635-7F89-4011-85B6-355C0082E4A6 Q36155239-1B031BB4-366E-46EC-A077-6D9DC469525F Q36171921-B661CC74-3696-42AF-B08C-369ADAC86AFB Q36345794-0363A039-7B69-4663-85E2-8332B9610ED2 Q36350069-23E94D69-21CD-45C0-8E40-3736AC4ABCDF Q36479531-F6720C12-1320-4E34-B620-A19D8419C81F Q36715570-4309F122-09DF-4DC3-83EF-028E761056E7 Q36907298-F0E1FA2A-62AD-4982-9693-9CE2A620A603 Q36909999-E301A152-FA8F-4DF9-8806-379A8B025272 Q37007243-0BAEE460-C673-4EE9-8657-38328C5B6B2A Q37008476-38C0EAEA-B3B6-41B4-87EC-F227F0489824 Q37364736-7098CF5A-8B77-4273-9F0A-6511EA05FB8B Q37397880-5FDC4CF1-8B28-4114-AD3B-8A9A25ADD010 Q37541469-09F58484-6B9E-4F9B-8DFA-F788D2190EF7 Q37562938-7EDCC4B6-A32B-498E-8645-716F76E9932C Q37635528-F0B7D1F6-2032-4F6C-9385-9125F5E7D23B Q37720518-9AB28EDF-96CA-4A57-AB90-BAF0269E502A Q38349779-46B761E4-E12B-460E-898E-55747CEA63B2

P2860

Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.

http://www.wikidata.org/entity/Q34433867

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.

@ast

Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.

@en

Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.

@nl

type

label

Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.

@ast

Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.

@en

Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.

@nl

prefLabel

Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.

@ast

Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.

@en

Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.

@nl

P1433

Q34433867-ECD1757E-FA35-4AD2-B077-64BE1CC58A40

P1476

Q34433867-8C3161C1-DDDF-4C1C-A60E-00A1F61E464B

P2093

Q34433867-0137B442-5ED9-4741-9C46-5F2A4A4718E9

Q34433867-0B240389-A446-4E9D-B27E-B5301EC58DDD

Q34433867-4CB707AF-66D7-4BFE-8F7C-67A511B5A38E

Q34433867-5806A9B6-CA43-4E29-891E-71342893E102

Q34433867-64FB7277-E765-479D-B5B2-0653F8B9226B

Q34433867-6CE70487-3E88-4C5A-8D21-BF56933618C4

Q34433867-746DCADD-D025-4DE8-AB36-6844E71A23C5

Q34433867-74DEAD60-FDDD-4E18-AD37-1C11AC62F397

Q34433867-960AD5FB-C3CC-4D0D-80EE-E3D2FE4ED24B

Q34433867-9927AA30-4C4E-463A-A6A9-598F04C14818

P2860

Q34433867-0AA466B2-7411-4C45-9D44-B571CF25F2AE

Q34433867-0E3A749D-0A51-43E0-9A74-87FDE736AECE

Q34433867-0FEC1B50-8B3E-49D0-9B55-19880281B462

Q34433867-24C362E0-C5CA-40D5-8BD3-997CD7105BA1

Q34433867-3F3C4ED7-A6AB-4E24-B0DD-BCDF9A19AF07

Q34433867-56C6B036-06D1-422E-98AC-B2A7E27D0646

Q34433867-676013A2-05D0-42AA-96A5-61BF519FE748

Q34433867-6B422EC8-60FF-4365-881F-37A617983640

Q34433867-6C587F27-5157-4B4D-AE77-21F351565976

Q34433867-81186E67-6DE7-4B00-8C3A-5E3C7F9A6C51

P2888

Q34433867-2E16511D-635B-4EA1-9312-049154A7CA15

P304

Q34433867-8275DC9D-03FF-4E94-BDDC-1C5AFB1F4A1E

P31

Q34433867-8647F76E-880D-41B6-A181-75B85CB70233

P356

Q34433867-7EA01828-1B39-4C7A-B32C-83070CC13EF9

P407

Q34433867-9F97BC9E-F2EA-426B-91F9-CA2123C762B2

P433

Q34433867-E20E6F3C-73EA-4E79-9AF3-707FA7BFE758

P478

Q34433867-8058E28F-4635-49C3-80CB-B5F5D31FB8AD

P50

Q34433867-640253FF-F185-41DC-A6FA-2F35F6D39B07

Q34433867-9DC7BF2D-B504-4507-8254-D39408FEBD2C

P577

Q34433867-3B7F6112-A922-4683-B012-530267898986

P5875

Q34433867-F7D62587-D9BE-4E43-ACC6-752572FF0968

P698

Q34433867-A3BE0C50-2C11-4FBB-B829-F74618555CFF

P921

Q34433867-AD33665B-AC64-4EAA-95EA-F0749CAC5FDF

P932

Q34433867-53F99FA3-AE9F-4F43-A59C-A0238D89B9D2

P356

P1433

Nature Medicine

P1476

Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition

@en

P2093

Angela M Christiano

http://www.w3.org/2001/XMLSchema#string

Annemieke de Jong

http://www.w3.org/2001/XMLSchema#string

Gina M DeStefano

http://www.w3.org/2001/XMLSchema#string

Jane E Cerise

http://www.w3.org/2001/XMLSchema#string

Julian Mackay-Wiggan

http://www.w3.org/2001/XMLSchema#string

Lisa Rothman

http://www.w3.org/2001/XMLSchema#string

Luzhou Xing

http://www.w3.org/2001/XMLSchema#string

Lynn Petukhova

http://www.w3.org/2001/XMLSchema#string

Pallavi Singh

http://www.w3.org/2001/XMLSchema#string

Raphael Clynes

http://www.w3.org/2001/XMLSchema#string

P2860

Genome-wide association study in alopecia areata implicates both innate and adaptive immunity

Janus kinase inhibitors in autoimmune diseases

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Abnormal interactions between perifollicular mast cells and CD8+ T-cells may contribute to the pathogenesis of alopecia areata.

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

Interleukin 15: biology and relevance to human disease.

Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).

A 'hairy' privilege.

Reprogramming of CTLs into natural killer-like cells in celiac disease

P2888

P304

1043-1049

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM.3645

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Claire A Higgins

P577

2014-08-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264830265

http://www.w3.org/2001/XMLSchema#string

P698

25129481

http://www.w3.org/2001/XMLSchema#string

P921

P932

4362521

http://www.w3.org/2001/XMLSchema#string